MBX Biosciences, Inc. — fact timeline

MBX Biosciences, Inc. shareholders approved Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-04 meeting.

“The Company's stockholders approved Proposal 2 to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 43,713,693 1,946 1,946 -”

MBX Biosciences, Inc. shareholders approved Election of two Class II directors to serve for a three-year term ending at the annual meeting of stockholders to be held in 2029. at the 2026-06-04 meeting.

“The Company's stockholders voted on the following matters, which are described in detail in the Proxy Statement: (i) to elect two Class II director nominees, Patrick J. Heron. and Edward T. Mathers, to the Company's Board of Directors, each to hold office until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal ("Proposal 1") and (ii) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 ("Proposal 2").”

MBX Biosciences, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026, was $23.5 million.

“Net loss for the three months ended March 31, 2026, was $23.5 million compared to a net loss of $23.9 million for the same period in 2025.”

MBX Biosciences, Inc. reported the full year ended December 31, 2025 results: net income $87.0 million.

“Net loss for the full year ended December 31, 2025 was $87.0 million”

MBX Biosciences, Inc. reported the three months ended December 31, 2025 results: net income $22.1 million.

“Net loss for the three months ended December 31, 2025, was $22.1 million”

MBX Biosciences, Inc. entered into Lease Agreement with 5 Burlington Woods, LLC valued at approximately $3.4 million (effective 2026-02-24).

“On February 24, 2026, MBX Biosciences, Inc. (the “Company”) entered into a lease agreement (the “Lease Agreement”) with 5 Burlington Woods, LLC ("5 Burlington Woods") to lease approximately 13,642 square feet of new office and laboratory space in Burlington, MA”

Carl L. Gordon departed as Director at MBX Biosciences, Inc..

“Also effective as of June 5, 2025 was the departure of Carl L. Gordon, Ph.D., CFA from the Company's board of directors.”

Steven L. Hoerter was appointed as director at MBX Biosciences, Inc..

“Effective as of April 7, 2025, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.”